Vyome Holdings (HIND) Profit After Tax (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Profit After Tax of -$962910.0 for Q1 2026, down 227.55% year-over-year from $754924.6 in Q1 2025, and up 26.23% quarter-over-quarter from -$1.3 million in Q4 2025.
Vyome Holdings (HIND) Profit After Tax (2015 - 2026) Analysis & Trends
Vyome Holdings' Profit After Tax history runs 12 years deep, the most recent figure standing at -$962910.0 for Q1 2026.
- In Q1 2026, Profit After Tax fell 227.55% year-over-year to -$962910.0; the TTM figure through Mar 2026 stood at -$11.2 million (down 592.13% YoY), while the FY2025 annual figure was -$10.5 million, down 625.64% from the prior year.
- Profit After Tax for Q1 2026 stood at -$962910.0, up from -$1.3 million in the prior quarter.
- The five-year high for Profit After Tax was -$127302.0 in Q1 2024, with the low at -$16.8 million in Q4 2022.
- The 5-year median for Profit After Tax is -$1.7 million (2023), against an average of -$4.2 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax jumped 95.22% in 2024, then sank 1469.14% in 2025.
- Vyome Holdings' Profit After Tax stood at -$16.8 million in 2022, then surged by 89.91% to -$1.7 million in 2023, then soared by 81.94% to -$306617.0 in 2024, then sank by 325.73% to -$1.3 million in 2025, then grew by 26.23% to -$962910.0 in 2026.
- Business Quant data shows HIND's Profit After Tax at -$962910.0 in Q1 2026, -$1.3 million in Q4 2025, and -$8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | -721,244.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -721,244.00 |
| Mar 31, 2026 | -962,910.00 |
| Dec 31, 2025 | -1.31 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -308,760.00 |
| Mar 31, 2025 | -293,973.00 |
| Dec 31, 2024 | -306,617.00 |
| Sep 30, 2024 | -547,772.00 |
| Jun 30, 2024 | -465,830.00 |
| Mar 31, 2024 | -127,302.00 |
| Dec 31, 2023 | -1.70 Mn |
| Sep 30, 2023 | -3.53 Mn |
| Jun 30, 2023 | -3.49 Mn |
| Mar 31, 2023 | -2.66 Mn |
| Dec 31, 2022 | -16.83 Mn |
| Sep 30, 2022 | -12.19 Mn |
| Jun 30, 2022 | -9.44 Mn |
| Mar 31, 2022 | -8.12 Mn |
| Dec 31, 2021 | -37.53 Mn |
| Sep 30, 2021 | -17.13 Mn |